Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Vaxil Bio Ltd.
No Price
Closing Price XTSX 27.04.2026:
0,29 CAD
27.04.2026 20:10
Current Prices from Vaxil Bio Ltd.
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
TSX-V
VXL.V
CAD
27.04.2026 20:10
0,29 CAD
-
Share Float & Liquidity
Free Float94,39 %
Shares Float2,59 M
Shares Outstanding2,74 M
Company Profile for Vaxil Bio Ltd. Share
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.
